ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: A Phase III Study
The study is being conducted to determine whether neoadjuvant endocrine therapy with
fulvestrant or the combination of anastrozole and fulvestrant, is better than anastrozole
when given before surgery to shrink the cancer and stop it from growing. Anastrozole inhibits
tumor growth by reducing the levels of estrogen and has been approved by the Food and Drug
Administration (FDA) of the United States for use after surgery for postmenopausal women with
estrogen receptor positive breast cancer. It is also considered a standard of care to give
anastrozole for a few months before surgery to shrink the tumor. Fulvestrant inhibits tumor
cell growth by reducing the levels of estrogen receptor in the tumor cell. It is not approved
by the FDA for use in women with early stage breast cancer before or after surgery, but is
approved by the FDA for patients with advanced (Stage 4) estrogen receptor positive breast
cancer that has spread to other parts of the body.
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.